In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Alpine Immune Sciences (ALPN), with a price target of $19.00. The company’s shares closed last Thursday at $8.16.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 15.8% and a 42.9% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alpine Immune Sciences with a $19.00 average price target.
See today’s analyst top recommended stocks >>
Based on Alpine Immune Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $688K and GAAP net loss of $9.93 million. In comparison, last year the company earned revenue of $567K and had a GAAP net loss of $11.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
